Emerging Trends and Hot Topics
The following abstracts have been identified by members of the
Annual Meeting Program Committee as representing the newest and
most innovative research being conducted in the various specialties.
To view abstracts, enter the program number below in the “Search”
field of the Online Abstract Search and Itinerary Builder.
107 amblyopia – EY
#3878. Visual Acuity and Refractive Error in an Unscreened Population of
Children. Jan Roelof Polling. May 8, 3:45pm.
#3880. Parental Understanding of Amblyogenic Factors in a Vision Screening
Program. Michaela L. Gruzensky. May 8, 3:45pm.
#3892. A Novel Active Game Therapy For Visual Recovery in Adult Amblyopia.
Indu Vedamurthy.May 8, 3:45pm.
#3893. Towards Establishing A New Treatment Protocol For Improving Stereovision In Patients With Amblyopia. Roger W. Li. May 8, 3:45pm.
#3895. Why Mothers Say ‘Look At Me When I’m Talking To You’: The Effect of
Amblyopia on Visual-Auditory Speech Perception. Robert J. Burgmeier. May
8, 3:45pm.
#3903. Enhanced Visual Recovery From Early Monocular Visual Deprivation
in Kittens Promoted by Short Periods of Darkness. Donald E. Mitchell. May 8,
3:45pm.
#5609. Effect of Compliance to Glasses Wear on the Outcome of Visual Acuity
after Refractive Adaptation. Gail Maconachie. May 10, 8:30am.
#5610. Pre-operative Visual Acuity and Contrast Sensitivity Deficits in Children
with Small, Partial, or Non-Central Cataracts. Eileen E. Birch. May 10, 8:30am.
110 AMD: clinical research – RE
#843. Adaptive Optics Retinal Imaging Demonstrates Macula Photoreceptor
Rescue, in 3 Patients with Good Visual Outcome, 6 to 8 years Post-Macular
Translocation Surgery for Neovascular Age-related Macular Degeneration.
Nick M. Muthiah. May 6, 11:15am.
#844. Comprehensive Atlas of RPE-Drusen Complex Thickness Maps for
Classification of Eyes with and without Intermediate AMD. Sina Farsiu. May 6,
11:15am.
#847. The Development of AMD in Participants with No or Small Drusen in the
Age-Related Eye Disease Study (AREDS). Grace C. Shih. May 6, 11:15am.
#861. Intravitreal Lucentis For The Treatment of Amd Related Pigment Epithelial Detachment. Yiannis Iordanous. May 6, 11:15am.
#865. Aggravation Of Neovascular Age-related Macular Degeneration During
The Induction Period Of Intravitreal Ranibizmab. Yusaku Yoshida. May 6,
11:15am.
Complete meeting information is available at www.arvo.org/am
101
Emerging Trends and Hot Topics
#867. Prevalence and Progression of Retinal Pigment Epithelial Atrophy in
Patients with Neovascular Age-Related Macular Degeneration treated with
Intravitreal Anti-VEGF Injections. Nishant Kumar. May 6, 11:15am.
#885. Effects Of Music Therapy On Intravitreal Injections: A Randomized Clinical Trial. Ron A. Adelman. May 6, 11:15am.
#2032. The Superdose Anti-VEGF (SAVE) Trial: 2.0-mg Intravitreal Ranibizumab for Recalcitrant Neovascular AMD, Two Year Endpoint Results. Eric
Chen. May 7, 1:45pm.
#2035. A Pilot Study of Combination Therapy for Neovascular AMD Using a
Single Injection of Liquid Sustained Release Intravitreal Triamcinolone Acetonide and Intravitreal Ranibizumab as Needed. Jennifer I. Lim. May 7, 1:45pm.
#2041. OCT response to 2mg ranibizumab for AMD Pigment Epithelial
Detachments refractory to conventional dosing in the HiPED study. Brandon G.
Busbee. May 7, 1:45pm.
#2042. Cumulative Incidence of Visual Acuity Change in the VIEW 1 and VIEW
2 Studies of Patients with Neovascular Age-related Macular Degeneration.
Daniel B. Roth. May 7, 1:45pm.
#2045. Efficacy Of The Systemic Complement Inhibitor Eculizumab In AMD
Patients With Drusen: The COMPLETE Study. Carlos Alexandre A. Garcia
Filho. May 7, 1:45pm.
#2046. Systemic Complement Inhibition With Eculizumab For The Treatment Of Geographic Atrophy In AMD Patients: The Complete Study. Zohar
Yehoshua. May 7, 1:45pm.
#2054. Index of Non-Circularity of Areas of Geographic Atrophy (GA) Is
Related to Progression Rate. Ronald P. Danis. May 7, 1:45pm.
#2893. Correlation of Retinal Morphology and Visual Acuity in the Comparison
of Age-Related Macular Degeneration Treatment Trial (CATT). Glenn J. Jaffe.
May 8, 8:30am.
#2894. Comparison of RC and Investigator Determined Retinal and Subretinal
fluid in the Comparison of Age-Related Macular Degeneration Treatment Trials
(CATT). Cynthia A. Toth. May 8, 8:30am.
#2905. Acquired Vitelliform Lesion Associated with Large Drusen. Luiz H.
Lima. May 8, 8:30am.
#2925. Untreated Obstructive Sleep Apnea Hinders Functional And Anatomical Response To Bevacizumab In Age Related Macular Degeneration. Yoreh
Barak. May 8, 8:30am.
#2926. Treat and Extend Therapy Cause Significant Changes to the Vitreous
Proteome in Patients with Wet AMD. Bert M. Glaser. May 8, 8:30am.
#2934. The NAT-2 Study: genetic analysis. Eric H. Souied. May 8, 8:30am.
102
Complete meeting information is available at www.arvo.org/am
Emerging Trends and Hot Topics
#2935. Omega-3, Essential and Monounsaturated Fatty Acid Deficiency in
Exudative Age-related Macular Degeneration: A survey from the NAT-2 Study.
Pascale Benlian. May 8, 8:30am.
#3081. Wide-field Spectral-domain Polarization-sensitive OCT (PS-OCT) For
Imaging Of The Retinal Pigment Epithelium (RPE) In Age-related Macular
Degeneration (AMD): From Bench To Bedside. Ursula Schmidt-Erfurth. May 8,
8:30am.
#3174. In-vivo Imaging of the Retinal Structure in Patients with Age-related
Macular Degeneration (AMD) with Adaptive Optics Scanning Laser Ophthalmoscopy (AOSLO). Yuhua Zhang. May 8, 1:45pm.
#3677. HARBOR Study: One-Year Results of Efficacy and Safety of 2.0 mg
versus 0.5 mg Ranibizumab in Patients with Subfoveal Choroidal Neovascularization Secondary to Age-Related Macular Degeneration. Ivan J. Suner. May
8, 3:45pm.
#3678. Subgroup Efficacy Analyses of the VIEW 1 and VIEW 2 Studies of
Intravitreal Aflibercept Injection and Ranibizumab for Treatment of Neovascular
AMD. Allen C. Ho. May 8, 3:45pm.
#3679. Year 7 Outcomes For Ranibizumab-treated Subjects In Anchor/marina:
A Multicenter, Prospective Cohort Study. Robert B. Bhisitkul. May 8, 3:45pm.
#3680. Incidence of Choroidal Neovascularization in the Fellow Eye Among
Patients Treated with Ranibizumab or Bevacizumab in the Comparison of Agerelated Macular Degeneration Treatments Trials (CATT). Maureen G. Maguire.
May 8, 3:45pm.
#3681. Baseline Predictors of Visual Acuity Response to Ranibizumab and
Bevacizumab in the Comparison of AMD Treatment Trial (CATT). Gui-Shuang
Ying. May 8, 3:45pm.
#3683. Cumulative Effect of High Risk Alleles in CFH, ARMS2 and VEGF on
Response to Ranibizumab Treatment in Age-Related Macular Degeneration.
Dzenita Smailhodzic. May 8, 3:45pm.
#4180. Visual Acuity and Injection Frequency Results of 2mg Ranibizumab
for Pigment Epithelial Detachments Refractory to Conventional Dosing in the
HiPED study. Anne E. Fung. May 9, 8:30am.
#5144. Passive Subretinal Space Associated With Retinal Pigment Epithelium
Detachment As False Positive For Exudative Age-related Macular Degeneration. Iuri Golubev. May 9, 1:45pm.
#5148. Prediction Of Retinal Pigment Epithelial Tears In Serous Vascularized
Pigment Epithelium Detachments. Christoph R. Clemens. May 9, 1:45pm.
#5153. Comparison Of Different Treatments For Retinal Angiomatous Proliferation. Marta Oldani. May 9, 1:45pm.
#5162. Feeder Vessel Navigated Laser Treatment In Non-responder Exudative
Age-related Macular Degeneration. Andrea Giani. May 9, 1:45pm.
Complete meeting information is available at www.arvo.org/am
103
Emerging Trends and Hot Topics
#5180. A Randomized Controlled Trial of Vision Self-Monitoring Tools in NonNeovascular Age-Related Macular Degeneration Subjects. Mark C. Roser.
May 9, 1:45pm.
#6514. Do Ultraviolet Radiations Induce Earlier Aged Ocular Pathologies
Among Mountaineer Guides? Hussam El Chehab. May 10, 11:15am.
#6515. Impact Of Visceral Fat, Serum Leptin Levels And High-sensitive Crp
Levels On The Pathogenesis Of Age-related Macular Degeneration. Paulina
Haas. May 10, 11:15am.
#6521. The Impact Of Anti-vegf Treatment On Vision-related Quality Of Life
In Age-related Macular Degeneration Outside Clinical Trials. Robert P. Finger.
May 10, 11:15am.
#6526. Clinical Features Of Self-resolving Sub-foveal Choroidal Neovascularisation in ‘Wet’ Age-Related Macular Degeneration. Sharmin Badiei. May 10,
11:15am.
111 AMD: epidemiology - CL
#6936. After Multiple Rounds of Mass Drug Administration for Trachoma, are
there only “Trachoma families” left? Sheila K. West. May 10, 1:15pm.
113 AMD: immunobiology – IM
#1232. A Role For Complement Activation In Preventing Retinal Degeneration.
Minzhong Yu. May 6, 3:15pm.
#1235. Low Influence Of C5A On Retinal Pigment Epithelial Cells. Susanne
Wasmuth. May 6, 3:15pm.
#5489. Cytokines in Patients with HLA-B27 + Acute Anterior Uveitis. Eva
Jakob. May 9, 3:45pm.
#6161. Non-professional Phagocytosis Can Play A Role In Herpesvirus Entry
Into Ocular Cells. Deepak Shukla. May 10, 8:30am.
116 AMD: preclinical studies - RC
#2023. Intravitreal Bevacizumab Activates Müller Cells And Astrocytes And
Reduces Carbonic Anhydrase In Retinas Of Monkeys: A Possible Explanation
For The Reduction Of Retinal Edema. Sylvie Julien. May 7, 1:45pm.
#2990. In-vivo Imaging Of A Fluorescent Probe Linked To Bevacizumab.
Alexander R. Cunea. May 8, 8:30am.
117 AMD: translational studies – RE
#2267. Efficacy Of Dexamethasone Sodium Phosphate Nanospheres Within
Thermo-responsive Hydrogel Treatment In A Laser Induced Choroidal Neovascularization Animal Model. Jennifer J. Kang Mieler. May 7, 3:45pm.
#5560. The Role Of Serping1 In Age-Related Macular Degeneration (amd)
Development. Charles O. Pierce. May 9, 3:45pm.
#5562. Transcranial Magnetic Stimulation Improves Retinal Function in an
Animal Model of Retinal Dystrophy. Ygal Rotenstreich. May 9, 3:45pm.
104
Complete meeting information is available at www.arvo.org/am
Emerging Trends and Hot Topics
#5562. Transcranial Magnetic Stimulation Improves Retinal Function in an
Animal Model of Retinal Dystrophy. Ygal Rotenstreich. May 9, 3:45pm.
123 antiangiogenic agents - PH
#2940. Treatment of Complicated Retinal Arterial Macroaneurysm with Intravitreal Bevacizumab. Simona Romano. May 8, 8:30am.
128 artificial vision, nanobiodevices, manipulation and
engineering - NT
#327. Electro-Mechanical Tactile Corneal Stimulation System for Vision Substitution. Michael Belkin. May 6, 8:30am.
131 bipolar cell structure and function - VN
#3156. GPR179, An Orphan G Protein-Coupled Receptor Is Critical To
Depolarizing Cell Function And Interacts With GRM6. Thomas A. Ray. May 8,
1:45pm.
#3157. Gpr179 Is Required For Depolarizing Bipolar Cell Function And Is
Mutated In Autosomal Recessive Complete Congenital Stationary Night Blindness. Maarten Kamermans. May 8, 1:45pm.
133 cataract surgery - LE
#1722. The Relationship of Cataract and Cataract Extraction to Age-related
Macular Degeneration: The Beaver Dam Eye Study. Barbara E. Klein. May 7,
1:45pm.
#6619. Aravind Pseudoexfoliation Study (APEX) I: Intraoperative Results. Alan
L. Robin. May 10, 11:15pm.
#6621. Reduced Laser Pulse Width Improves Cutting Efficiency in Laser
Refractive Cataract Surgery. Simone Schneider. May 10, 11:15am.
#6622. Morphology of Femtosecond Intrastromal Arcuate Incisions. Perry S.
Binder. May 10, 11:15am.
#6637. Silicone Sleeve Polishing Of Posterior Capsule, A Safe And Costless
I/A Technique. Jean-Marie Giraud. May 10, 11:15am.
#6639. Corneal Astigmatism And Its Correction With The Toric Intraocular Lens
And Peripheral Corneal Relaxing Incisions. Li Wang. May 10, 11:15am.
#6669. Retrospective Evaluation of Tecnis Multifocal (ZMA00 or ZMB00) and
ReSTOR (SN60D1) Intraocular Lenses Following Phacoemulsifcation. Gabriela Perez. May 10, 11:15am.
#6683. Is Topical Ketorolac Tromethamine 0.4% Ophthalmic Solution Needed
for Cataract Surgery? A Randomized Controlled Trial. Flavia G. Ticly.
May 10, 11:15am.
#6684. Efficacy of Low-Concentration, Modified Bromfenac Ophthalmic Solution Administered Once Daily for Ocular Inflammation and Pain Associated
with Cataract Surgery. Sharon M. Klier. May 10, 11:15am.
Complete meeting information is available at www.arvo.org/am
105
Emerging Trends and Hot Topics
#6687. Long Term Complications and Visual Outcomes of Anterior Chamber
versus Posterior Chamber Intraocular Lens Implants after Phacoemulsification
in Patients with Uveitis. Jonathan N. Kruh. May 10, 11:15am.
#6697. Intraocular Pressure Response in Glaucoma Patients Using Difluprednate 0.5% Post Operatively after Phacoemulsification. Melissa M. Cable.
May 10, 11:15am.
#6714. Comparison of Predicted Refractions to Outcome Refractions in
Patients Undergoing Combined Macula Surgery and Phacoemulsification
Versus Patients Undergoing Phacoemulsification Alone. Amilia Schrier. May
10, 11:15am.
#6716. The accuracy of intraocular lens formulas in children ages 2 to 18 at
Children’s Medical Center of Dallas. Zachary Vest. May 10, 11:15am.
#6731. Biometric Parameters Before And After Mydriasis. Jonathan Shahar.
May 10, 11:15am.
135 cataractogenesis - LE
#1055. Isolation And Characterization Of A Novel Aldose Reductase Inhibitor
From Emblica officinalis. Jonathan M. Petrash. May 6, 11:15am.
#1723. FYCO1 Mutation Hotspot in Congenital Cataract. Hana Abouzeid.
May 7, 1:45pm.
#3049. Age-related Light Scattering Development in Non-Cataractous Lenses
from Diabetic Patients and Possible Biochemical Mechanisms to Explain this
Observation. Alfred R. Wegener. May 8, 8:30am.
137 choroidal neovascularization - RE
#1152. Non-invasive Vascular Imaging of Exudative Macular Disease by High
Penetration Doppler Optical Coherence Angiography. Young-Joo Hong. May 6,
3:15pm.
#3825. Preferential Hyperacuity Perimetry Home Monitoring in Patients Following Treatment for Neovascular Age-related Macular Degeneration. Merina
Thomas. May 8, 3:45pm.
138 circadian rhythms: basic mechanisms - RC
#4329. Circadian Clock Gene Rhythms In Human Retina Müller Cells And
Their Inhibition By Sirna Knockdown Of Period Genes. Lili Xu. May 9, 8:30am.
144 contact lens - CO
#4692. Association Of Single Nucleotide Polymorphisms Of Interleukins 1β,
6 And 12b With Contact Lens Keratitis Susceptibility And Severity. Nicole A.
Carnt. May 9, 1:45pm.
#6112. Contact Lens/Contact Lens solution Combinations Determine the
Inflammatory Changes on the Ocular Surface: A Laser In Vivo Confocal
Microscopy Study. Bernardo M. Cavalcanti. May 10, 8:30am.
106
Complete meeting information is available at www.arvo.org/am
Emerging Trends and Hot Topics
#6300. Decreasing Peripheral Hyperopia With Distance-centre Relativelyplus Powered Periphery Contact Lenses Reduced The Rate Of Progress Of
Myopia: A 5 Year Vision Crc Study. Brien A. Holden. May 10, 11:15am.
148 cornea: stroma and keratocytes - CO
#3643. Intracellular Degradation/Retention of Mutant C-terminal Truncated
Decorin In Human Congenital Stromal Corneal Dystrophy. Shoujun Chen. May
8, 3:45pm.
#3645. The Influence of Fibril Associated Collagens with Interrupted Triple Helices (FACITS) on Murine Corneal Endothelial Structure and Function. Edgar
M. Espana. May 8, 3:45pm.
153 corneal dystrophies and genetics - CO
#1740. An Association between an Expanded Trinucleotide Repeat in Transcription Factor 4 (TCF4, E2-2) and Fuchs Corneal Dystrophy. Keith H. Baratz.
May 7, 1:45pm.
159 corneal transplantation - CO
#3138. Immunologic Rejection Risk with Four Transplant Techniques for Endothelial Dysfunction. Marianne O. Price. May 8, 1:45pm.
160 corneal wound repair and healing - CO
#1815. Corneal confocal microscopy detects improvements in nerve morphology after simultaneous Pancreas and Kidney transplantation (SPK) in type 1
diabetic patients. Mitra Tavakoli. May 7, 1:45pm.
161 cytokines and growth factors - PH
#6288. Human Tears Reveal Insights Into Corneal Neovascularization. Nadia
Zakaria. May 10, 8:30am.
162 diabetic macular edema: clinical research - RE
#379. Evaluating A New Clinical Grading Protocol For Diabetic Macular
Edema. Matthias Bolz. May 6, 8:30am.
#387. Twelve-month Treatment With Intravitreal Bevacizumab For Diabetic
Macular Edema In A “Real World” Clinical Setting. Paolo Lanzetta. May 6,
8:30am.
#394. Effect Of Diabetic Macular Edema On Peripapillary Retinal Nerve Fiber
Layer Thickness Profiles. Duck Jin Hwang. May 6, 8:30am.
#409. Diabetic Macular Edema: Scanning Laser Ophthalmoscope in the Retro
Mode versus Standard Imaging. Stela Vujosevic. May 6, 8:30am.
#1337. Integrin Peptide Therapy: A New Class of Treatment for Vascular Eye
Diseases - The First Human Experience in DME. David S. Boyer. May 7,
8:30am.
#4664. Efficacy And Safety Of Ranibizumab 0.5 Mg As Monotherapy Or
Adjunctive To Laser Versus Laser Monotherapy In Asian Patients With Visual
Impairment Due To Diabetic Macular Edema: 12-month Results Of The
REVEAL Study. Masahito Ohji. May 9, 1:45pm.
Complete meeting information is available at www.arvo.org/am
107
Emerging Trends and Hot Topics
#4668. Comparison of Treatment of Fellow Eyes treated with Ranibizumab with
Study Eye of Patients Enrolled in the READ-3 Study. Afsheen A. Khwaja.
May 9, 1:45pm.
#5282. 6 Month Results of the READ 3 Study: Ranibizumab for Edema of the
Macula in Diabetes. Diana V. Do. May 9, 3:45pm.
163 diabetic retinopathy: angiogenesis – RC
#5758. COMPAng1 Prevents Decreases in Visual Acuity and Retinal Thinning
in the Diabetic Mouse. Judd M. Cahoon. May 10, 8:30am.
164 diabetic retinopathy: biochemical and molecular disease
mechanisms - BI
#2407. Normalization of Fatty Acid Elongase ELOVL4 In Diabetic Retina
Prevents Vascular Degeneration and Inflammation Through Modification of
Sphingolipid Metabolism. Matthew S. Faber. May 7, 3:45pm.
#5584. Alzheimer Retina Pathology in a Novel Animal Model of Neuropathology in Diabetes. Peter Frederikse. May 10, 8:30am.
165 diabetic retinopathy: cell biology - RC
#360. Angiofibrotic Response To VEGF Inhibition In Membranes Extracted
During Diabetic Vitrectomy: Results Of A Randomized, Controlled, Translational Study. Elliott H. Sohn. May 6, 8:30am.
#5405. Retinopathy in a Cone-Rich Rodent Model of Spontaneous Type 2
Diabetes. Mandy Hong.May 9, 3:45pm.
#5408. Epigenetic Alterations of Endothelial Cell Junction Molecules: Role of
Metabolic Memory in the Development of Diabetic Macular Edema. Sampathkumar Rangasamy. May 9, 3:45pm.
#5423. Notch-mediated Cell-cell Interactions In The Pathophysiology Of
Diabetic Retinopathy. Joseph F. Arboleda-Velasquez. May 9, 3:45pm.
#5427. Loss Of Bone Marrow Innervation Leads To Inadequate Repair Of
Retinal Vessels In Diabetic Retinopathy Animal Model. Priyanka Pandey.
May 9, 3:45pm.
166 diabetic retinopathy: clinical research - RE
#346. Comparison Of Intravitreal Bevacizumab Alone Or Combined With
Triamcinolone Versus Triamcinolone In Diabetic Macular Edema: A Randomized Clinical Trial. Minchul Shin. May 6, 8:30am.
#358. The Diabetic Retinopathy Repair Project - Prevalence And Prognostic
Significance Of Ischaemia In Diabetic Macula Disease. Dawn A. Sim.
May 6, 8:30am.
#1335. Ranibizumab Dose and Treatment Interval Comparison for the Treatment of Diabetic Macular Edema: Final Two Year Results. Philip J. Ferrone.
May 7, 8:30am.
#2860. Phenotypes of Diabetic Retinopathy Progression to CSME based on
Non-Invasive Examinations. Sandrina Nunes. May 8, 8:30am.
108
Complete meeting information is available at www.arvo.org/am
Emerging Trends and Hot Topics
#2863. Microperimetry assessment of retinal sensitivity in patients with
diabetic macular edema - results from the Phase 2 Da Vinci study. Victor H.
Gonzalez. May 8, 8:30am.
#2864.Scotopic Microperimetry in Diabetes. Edoardo Midena. May 8, 8:30am.
#2870. Skin Autofluorescence Is Associated with Current Stage of Diabetic
Retinopathy. Masayuki Yasuda. May 8, 8:30am.
#2884. Reliability of Patient-reporting of Pan-retinal Photocoagulation (PRP)
Compared to Fundus Photograph Assessment in Sixteen Years of the Epidemiology of Diabetes Interventions and Complications Study (EDIC). Wanjie
Sun. May 8, 8:30am.
#5278. Protection from Proliferative Diabetic Retinopathy in Patients with 50 or
More Years of Type 1 Diabetes. Jerald E. Wisdom. May 9, 3:45pm.
#5281. The Relationship of Diabetic Nephropathy to Retinopathy and Macular
Edema in Type 2 Diabetes: The Diabetes Management Project. Ecosse L.
Lamoureux. May 9, 3:45pm.
171 diabetic retinopathy: preclinical studies - RC
#306. Regenerative Therapeutic Potential of Adipose Stromal Cells in Early
Stage Diabetic Retinopathy. Gangaraju Rajashekhar. May 6, 8:30am.
#5764. Overexpression of IL-1 Receptor Antagonist in the Rat Retina by
AAV2-mediated Gene Transfer Prevents Capillary Loss in Experimental Diabetes. Chiara Gerhardinger. May 10, 8:30am.
172 drug and gene delivery systems - PH
#483. Pharmacokinetics of intravitreal bevacizumab (Avastin) In vitrectomized
eyes. Se Joon Woo. May 6, 8:30am.
#503. Development Of Drug Loaded Nanofiber Sutures For Ophthalmologic
Application. Fabiana K. Kashiwabuchi. May 6, 8:30am.
#4642. Update on QLT091001 in Subjects with Leber Congenital Amaurosis
(LCA) due to Lecithin:Retinol Acyltransferase (LRAT) or Retinal Pigment
Epithelial 65 Protein (RPE65) mutations: Longer-term follow-up of subjects
originally treated with 7-day therapy. Robert K. Koenekoop. May 9, 1:45pm.
173 drug delivery: iris-ciliary body/intraocular fluids/
posterior segment - PH
#496. Degradation And The Routes Of Clearance Of Intravitreal Hydrosilylated
Porous Silicon Particles. Lingyun Cheng. May 6, 8:30am.
174 dry eye disease - CO
#598. Influence of Isotretinoin on Human Meibomian Gland Epithelial Cells.
Juan Ding. May 6, 11:15am.
#1283. A Newly Developed Noninvasive and Mobile Pen-shaped Meibography
System. Reiko Arita. May 7, 8:30am.
Complete meeting information is available at www.arvo.org/am
109
Emerging Trends and Hot Topics
178 endophthalmitis: clinical - RE
#1675. Bacterial Susceptibility Profiles in Trauma Associated Endophthalmitis.
Duncan A. Friedman. May 7, 8:30am.
#1678. Infectious Keratitis Progressing To Endophthalmitis: A 15-year-study Of
Risk Factors, Microbiology, And Clinical Outcomes. Christopher R. Henry.
May 7, 8:30am.
#1691. Antibacterial Properties of 2% Lidocaine on Staphylococcus Aureus,
Staphylococcus Epidermidis, and Streptococcus Viridans and Reduced Rate
of Post-injection Endophthalmitis. Stephen J. Kim. May 7, 8:30am.
#2252. An Outbreak of Streptococcus Endophthalmitis After Intravitreal Bevacizumab. Roger A. Goldberg. May 7, 3:45pm.
#4181. Changes in Ocular Flora in Eyes Exposed to Macrolide or Fluoroquinolone Ophthalmic Antibiotics: A Prospective, Controlled, Longitudinal Study.
Sarita B. Dave. May 9, 8:30am.
#4182. Eliminating Antibiotic Prophylaxis For Intravitreal Injections: A Consecutive Series of 15,029 Injections by a Single Surgeon. Abdhish R. Bhavsar .
May 9, 8:30am.
#4183. Laboratory Investigation of an Endophthalmitis Outbreak Caused by
Streptococcus Mitis/Oralis Group After Intravitreal Injection of Avastin. Harry W.
Flynn, Jr. May 9, 8:30am.
179 epigenetics - BI
#5585. Rescue Of Photoreceptor Degeneration In Rd1 Mice By Systemic
Treatment With Valproic Acid. Kenneth P. Mitton. May 10, 8:30am.
181 extraocular muscles and associated tissues - EY
#2220. Myocyte Dedifferentiation Underlies Zebrafish Extraocular Muscle
Regeneration: An Expanding Paradigm For Therapeutic Tissue Regeneration.
Alon Kahana. May 7, 3:45pm.
182 eye movements - EY
#513. Optical Treatment Of Nystagmus - A Randomised, Controlled, Crossover Study. Pavitra Jayaramachandran. May 6, 8:30am.
#4851. Evaluation Of MTBI Subjects Using An Eye-movement-based Testing
Suite. Jonathan B. Jacobs. May 9, 1:45pm.
#4852. The Use of Eye Movements to Accurately Diagnose Combat-Related
Mild TBI. Paul A. Wetzel. May 9, 1:45pm.
#4868. The Effect Of 3D Displays Upon Adaptative Components Of The
Accommodation And Vergence Systems. Laura E. Sweeney. May 9, 1:45pm.
#5606. Uncorrected Antisaccade Errors Predict Cognitive Problems After Mild
Traumatic Brain Injury In Younger Children. Larry A. Abel. May 10, 8:30am.
#5607. Fatigue and Hypoglycemia Impair Saccade Velocity and Accuracy but
not Visual Perception. Benjamin Thompson. May 10, 8:30am.
110
Complete meeting information is available at www.arvo.org/am
Emerging Trends and Hot Topics
184 ganglion cell structure and function - VN
#6914. What Information Does The Eye Send To The Brain? Recording The
Entire Visual Output At A Single Retinal Location. Tom Baden. May 10, 1:15pm.
186 gene therapy and delivery - PH
#1885. Efficient Transduction of Tyrosine-to-Phenylalanine Mutated AAV2
Vectors Carrying Human ND4 Gene and Biodistribution Following Intravitreal
Delivery in a Rodent Model- a Gene Therapy for Leber Hereditary Optic
Neuropathy. Rajeshwari D. Koilkonda. May 7, 1:45pm.
#1926. Pre-clinical Gene Therapy Studies In Choroideremia Mouse Models
Using AAV Vectors. Miguel C. Seabra. May 7, 1:45pm.
#1934. Establishing A Course For AAV-mediated Gene Therapy For Leber
Congenital Amaurosis-1 (LCA1). Shannon E. Boye. May, 1:45pm.
#1936. Lentiviral Vector Gene Replacement Therapy in Stargardt Disease and
Usher Syndrome type Ib. J T. Stout. May 7, 1:45pm.
#5576. A Comparative Evaluation Of Translational Read-through Inducing
Drugs For Treatment Of Ush. Kerstin Nagel-Wolfrum. May 10, 8:30am.
#5577. Gene Therapy For Choroideremia - Initial Report On A New Clinical
Trial. Robert E. MacLaren. May 10, 8:30am.
#5579. Suppression of the Neurodegeneration of Experimental Optic Neuritis
by Single-subunit Yeast NADH-Ubiquinone Oxidoreductase (NDI1). Venu Talla.
May 10, 8:30am.
187 gene therapy: nonviral and viral vectors - PH
#1900. Correction of Cryptic Splicing in Usher Syndrome Using Antisense
Oligonucleotides. Jennifer J. Lentz. May 7, 1:45pm.
#1901. AAV-mediated Gene Therapy Restores Retinal Function And Vision In
The PDE6β-deficient Dog. Lolita Monnier. May 7, 1:45pm.
#1919. AAV2/5 Mediated Gene Augmentation Rescues Photoreceptors in
Canine Models of RPGR-XLRP. William A. Beltran. May 7, 1:45pm.
191 glaucoma: neuroprotection - GL
#4676. TGFβ Potentiates Retinal Ganglion Cell Death After Optic Nerve Injury.
James T. Walsh. May 9, 1:45pm.
192 glaucoma: biochemistry and molecular biology, genomics
and proteomics - BI
#3829. Endogenous Lipids as Regulators of Intraocular Pressure in Glaucoma.
Sanjoy K. Bhattacharya. May 8, 3:45pm.
#3841. Comparison of Serum Homocysteine, Vitamin B12, Vitamin B6, and
Folate Levels in Different Types of Glaucoma. Joo Hwa Lee. May 8, 3:45pm.
Complete meeting information is available at www.arvo.org/am
111
Emerging Trends and Hot Topics
#3860. Chemokine Receptor Antagonist Lowers Intraocular Pressure and
Prevents Retinal Degeneration in an Animal Model Glaucoma. Alexandre
Denoyer. May 8, 3:45pm.
#3867. Discovery and SAR of a Class of Ocularly-active Compounds Displaying a Dual Mechanism of Activity for the Treatment of Glaucoma. Mitchell A.
deLong. May 8, 3:45pm.
#6315. Hmgb-1 Induces Apoptosis In Retinal Ganglion Cells And Intraretinal
Inflammation By Activation Of Tlr4 And Cytokine Release. Maurice Schallenberg. May 10, 11:15am.
#6316. Lipidomics of glaucomatous optic nerve tissue via MALDI Imaging.
Franz H. Grus. May 10, 11:15am.
#6317. Amyloid Fibril Formation By The Olfactomedin Domain Of Myocilin.
Raquel L. Lieberman. May 10, 11:15am.
193 glaucoma: biomechanics - GL
#1747. Laminar Microarchitecture (LMA) Change in the Non-human Primate
(NHP) Unilateral early Experimental Glaucoma (EG) Model. Claude F. Burgoyne. May 7, 1:45pm.
#3182. 3D Deformation Mapping of the Human Optic Nerve Head In Vivo.
Michael J. Girard. May 8, 1:45pm.
#3184. Median Pore Size And Beam Thickness Are Good Predictors Of Median IOP-Induced Shear Strain Within The Lamina Cribrosa Microarchitecture.
Ian A. Sigal. May 8, 1:45pm.
#3186. Scleral Shell Stiffening in Severe Experimental Glaucoma in the Nonhuman Primate (NHP). J Crawford C. Downs. May 8, 1:45pm.
#5062. Parapapillary Atrophy in Patients with Intracranial Tumors. Jost B.
Jonas. May 9, 1:45pm.
194 glaucoma: clinical drug studies and clinical trials - GL
#5095. A Phase 2 Study Evaluating Safety and Efficacy of the Latanoprost
Punctal Plug Delivery System (L-PPDS) in Subjects With Ocular Hypertension
(OH) or Open-Angle Glaucoma (OAG). Damien F. Goldberg. May 9, 1:45pm.
#6355. Three Year Results of the Ahmed Baerveldt Comparison (ABC) Study.
Donald L. Budenz. May 10, 11:15am.
196 glaucoma: epidemiology - CL
#4417. Fear of Falling in Glaucoma. Pradeep Y. Ramulu. May 9, 8:30am.
#4479. A Critical Evaluation of Evidence for Visual Field Improvement in the
CIGTS. David C. Musch. May 9, 8:30am.
197 glaucoma: genetics - GL
#4493. CDKN2BAS Genotype - Glaucoma Phenotype Correlations In The
GLAUGEN Study And The NEIGHBOR Consortium. Louis R. Pasquale. May
9, 8:30am.
112
Complete meeting information is available at www.arvo.org/am
Emerging Trends and Hot Topics
#4516. Parameterized Analysis of Weighted Variants in Blended Cohorts
Optimizes Analysis of Exomes from Primary Open Angle Glaucoma Cases
from the NEIGHBOR Study. Terry Gaasterland. May 9, 8:30am.
#5291. Genome-wide Analysis Of Central Corneal Thickness In POAG Cases
From The NEIGHBOR Consortium. Megan Ulmer. May 9, 3:45pm.
#5292. Common Variants in 9p21 and 8q23 are associated with Normal Tension Glaucoma: Results From The NEIGHBOR and GLAUGEN Genome-wide
Association Studies. Janey L. Wiggs. May 9, 3:45pm.
#5293. Targeted Resequencing of CDKN2BAS Locus Identifies Variants Associated with Primary Open Angle Glaucoma. Michael A. Hauser. May 9, 3:45pm.
#5295. Open Angle Glaucoma In Soluble Guanylate Cyclase α1-deficient Mice
And Its Association With The Gucy1a3/gucy1b3 Locus In Humans. Emmanuel
S. Buys. May 9, 3:45pm.
198 glaucoma: IOP measurement and characterization - GL
#4171. Safety And Reproducibility Of Patterns Of Repeated Continuous 24hour Iop Monitoring With An Ocular Telemetry Device. Kaweh Mansouri. May
9, 8:30am.
199 glaucoma: laser therapy - GL
#6350. Transient Corneal Endothelial Changes Associated With Selective
Laser Trabeculoplasty. Andrew J. White. May 10, 11:15am.
201 glaucoma: pharmacological intervention or cellular
mechanism - GL
#1749. Latanoprost Stimulates Lymphatic Drainage from the Mouse Eye. Alex
L. C. Tam. May 7, 1:45pm.
#1750. Rationally Designed, Controlled-release Glaucoma Treatments Achieve
One Month Of Iop Reduction With A Single Dose. Morgan V. Fedorchak. May
7, 1:45pm.
#6612. Enhancement Of Stem Cell Integration Into The Retina By Modulating
Glial Reactivity In An In vitro Stem Cell Transplantation Model. Alessia Tassoni.
May 10, 11:15am.
202 glaucoma: structure/function relationships - GL
#215. Does Glaucoma have a Short Memory? Shaban Demirel. May 6,
8:30am.
#218. Latent Class Regression (LCR) Analysis for Detecting Glaucoma
Progression. Gadi Wollstein. May 6, 8:30am.
#1748. Mice with an Induced Mutation in Collagen 8A2 Exhibit Axial Elongation and Are Resistant to Retinal Ganglion Cell Damage in an Experimental
Glaucoma Model. Frances E. Cone. May 7, 1:45pm.
#5619. Evaluating A ‘Random Forest’ Decision Tree Classifier To Identify Eyes
With Glaucomatous Visual Field Loss Applied To Measurements From Multiple
Imaging Devices. Ryo Asaoka. May 10, 8:30am.
Complete meeting information is available at www.arvo.org/am
113
Emerging Trends and Hot Topics
#5624. Correlation of Brain Volumes and Functional Deficits in Glaucoma.
Alice L. Williams. May 10, 8:30am.
#6604. Retinal ganglion cell morphology is not affected by chronic experimental glaucoma in mice selectively expressing Yellow Fluorescent Protein.
Giedrius Kalesnykas. May 10, 11:15am.
204 glaucoma: trabecular meshwork and ciliary body - GL
#2743. Optical Coherence Tomography (OCT) Imaging of Pulse-induced
Trabecular Meshwork (TM) Movement Ex Vivo in Non-human Primates. Murray
A. Johnstone. May 8, 8:30am.
205 glaucoma: visual fields and psychophysics - GL
#1751. Seasonal Variations in Sensitivity and Intraocular Pressure (IOP) in
the Ocular Hypertension Treatment Study (OHTS). Stuart K. Gardiner. May 7,
1:45pm.
#2264. Examining Visual Field Loss In Patients With Glaucoma During Their
Predicted Remaining Lifetime. David P. Crabb. May 7, 3:45pm.
#2266. Regression Modeling for Pointwise Visual Field Perimetry Data for
Patients with Glaucoma. Dennis Mock. May 7, 3:45pm.
206 glial cells - RC
#2005. Neuroprotection and Inhibition of Blood-Retinal Barrier Breakdown In
a Transgenic Model of Conditional Müller Cell Ablation. Weiyong Shen. May 7,
1:45pm.
211 imaging of the retina in health and disease - MOI
#3106. Non-mydriatic, 68° Wide Fundus Imaging with Low Cost Components.
Bernhard Hoeher. May 8, 8:30am.
213 imaging: clinical applications - MOI
#4986. Pharmacokinetic Properties Of Intravitreally Placed I-124 Radiolabeled
Bevacizumab And Ranibizumab After Vitrectomy And Lensectomy In A Rabbit
Model. John B. Christoforidis. May 9, 1:45pm.
214 imaging: cornea - CO
#4192. Evaluation of Treatment with Cyclodextrin, Allopregnanolone and Miglustat for Niemann-Pick Disease type C1 in a Knock-out Mouse Model. Marine
Hovakimyan, May 9, 8:30am.
#6303. Keratoconus Detection by Corneal Epithelial Thickness Mapping with
Fourier-Domain Optical Coherence Tomography. Yan Li. May 10, 11:15am.
215 imaging: glaucoma - GL
#1745. Enhanced Glaucoma Detection With An Anatomically Accurate
Spectral Domain OCT Derived Neuroretinal Rim Parameter. Balwantray C.
Chauhan. May 7, 1:45pm.
#1746. Does Reflectance Speckle of Retinal Nerve Fiber Layer Relate to
Axonal Activity? Xiang-Run Huang. May 7, 1:45pm.
114
Complete meeting information is available at www.arvo.org/am
Emerging Trends and Hot Topics
#2744. Schlemm’s Canal (SC) Cross-sectional Area (CSA) and Shape Fluctuation. Jessica E. Nevins. May 8, 8:30am.
#3277. In vivo Identification and Classification of the Schlemm’s Canal-Collector Channel Junctions in Normal Eyes Using Serial High Definition Anterior
Segment Fourier-domain OCT. Alfredo R. Castillejos. May 8, 1:45pm.
#3696. Improved Reproducibility of SD-OCT Laminar Cribrosa Thickness
Measurement Using Maximum Intensity Projection Image. Tae-Woo Kim. May
8, 3:45pm.
#3697. High-resolution Longitudinal Examination Of The Lamina Cribrosa
And Optic Nerve Head In Living Non-human Primates With Experimental
Glaucoma. Kevin M. Ivers. May 8, 3:45pm.
216 imaging: image guided therapy and monitoring - PH
#5397. Assessment of Macular Hole Dynamics Utilizing Intraoperative Optical
Coherence Tomography. Justis P. Ehlers. May 9, 3:45pm.
219 imaging: new technologies and techniques - MOI
#807. 3-D Image Guided Retinal Surgery Using Real-Time High-Speed
Fourier-Domain Optical Coherence Tomography. Peter L. Gehlbach. May 6,
11:15pm.
#3090. High-Resolution Confocal Full Polarimeter For The Living Human
Retina. David Lara. May 8, 8:30am.
220 imaging: OCT advances in technology - MOI
#795. Rates of False Positive Peripapillary and Macular Optical Coherence Tomography Scans in Healthy Myopic Eyes: Cirrus HD-OCT versus RTVue-100.
Jean-Claude Mwanza. May 6, 11:15am.
#797. Retinal Neovascularization Secondary to Proliferative Diabetic Retinopathy Characterized by Spectral Domain Optical Coherence Tomography. Hyung
Cho. May 6, 11:15am.
#2123. Retinal and Choroidal Thickness measured by Swept-source Optical
Coherence Tomography in the Population-based Rotterdam Study. Caroline C.
Klaver. May 7, 1:45pm.
#2129. Choroidal Thickness Measurements During CSCR Treatment. Caroline
Brandl. May 7, 1:45pm.
#3623. Anterior Segment OCT (RTVue) for Diagnostic Imaging of Ocular
Surface Pathology. Fouad E. Sayyad. May 8, 1:45pm.
#5257. Split-Spectrum Amplitude-Decorrelation Angiography with Optical
Coherence Tomography. Yali Jia. May 9, 3:45pm.
#5259. Ultra high-speed swept source Fourier domain mode locking (FDML)
OCT at 1.68, 3.3 and 6.7 MHz - Image quality of retinal cross sectional scans.
Lukas Reznicek. May 9, 3:45pm.
Complete meeting information is available at www.arvo.org/am
115
Emerging Trends and Hot Topics
221 imaging: posterior segment, clinical - RE
#1754. Baseline Indocyanine Green Angiography Characteristics of Polypoidal
Choroidal Vasculopathy in a Randomised Controlled Trial. Tock H. Lim. May 7,
1:45pm.
#1755. Predictive Value of the Area of Peripheral Retinal Non-Perfusion on
Treatment Response in Branch and Central Retinal Vein Occlusion. Colin S.
Tan. May 7, 1:45pm.
#2643. Optical Coherence Tomography Imaging of Sub-Retinal Pigment
Epithelium Lipid. Sri Krishna Mukkamala. May 7, 3:45pm.
#2651. Quantitative Reproducibility Assessment Of Rpe Lesions In Patients
With Choroidal Neovascularization Related To Neovascular Age-related Macular Degeneration Using Polarization-sensitive Oct. Christopher Schuetze. May
7, 3:45pm.
#2663. Multimodal Line Scanning Device for Detection and Treatment of
Retinal Diseases. Deeba Husain. May 7, 3:45pm.
#2674. Is Visual Acuity an Accurate Predictor of Macular Sensitivity? Visual
Acuities as Measured by the ETDRS Chart and by the Potential Acuity Meter
as Predictors of Macular Sensitivity Measured by an Automatic Fundus Perimetry/Tomography System. Elham Hatef Naimi. May 7, 3:45pm.
#2678. Cone Photoreceptor Structure in Achromatopsia. Venki Sundaram. May
7, 3:45pm.
#2680. Optical Coherence Tomography Anatomical and Functional Evaluation of Ganglion Cell Complex after Surgical Removal of Idiopatic Epiretinal
Membranes. Lorenzo Iuliano. May 7, 3:45pm.
#3171. Choroidal Thickness In Patients With Central Serous Chorioretinopathy
And Myopia. Irene A. Barbazetto. May 8, 1:45pm.
222 imaging: small animal models - MOI
#4987. Analysis of Total Retinal Blood Flow in Normal and Diabetic Rats with
Ultrahigh-Speed Spectral / Fourier Domain OCT. Woo Jhon Choi. May 9,
1:45pm.
223 imaging: ultrasound - MOI
#4980. Non-invasive, Targeted Gene Delivery to Retina and Retinal Endothelial
Cells and Enhanced Live Retinal Imaging Using Contrast-enhanced Ultrasound Delivery System. Colleen Cowan. May 9, 1:45pm.
225 immunohistochemistry - AP
#5617. Molecular Histopathology Using Gold Nanorods And Optical Coherence Tomography. Jared L. Matthews. May 10, 8:30am.
227 intraocular pressure/physiology pharmacology - PH
#1961. A Novel Hypothesis: The Dorsomedial Hypothalamus Regulates Circadian Fluctuations of Intraocular Pressure. Brian C. Samuels. May 7, 1:45pm.
116
Complete meeting information is available at www.arvo.org/am
Emerging Trends and Hot Topics
#1976. Effect of Commonly Used Topical Anesthetics on Intraocular Pressure
Measurements. Nathan Welch. May 7, 1:45pm.
#3670. Dopamine-3 Receptor Modulates Intraocular Pressure. Claudio Bucolo.
May 8, 3:45pm.
228 intravitreal/periocular local therapies - RE
#873. Bilateral Intravitreal Injections: safety analysis. Gian S. Pierozzi. May 6,
11:15am.
#884. Needle Size in Intravitreal Injections-Preliminary Results of a Randomized Clinical Trial. Christiane I. Falkner-Radler. May 6, 11:15am.
#904. Combined Inhibition of Tumor Necrosis Factor (TNF) and Vascular Endothelial Growth Factor (VEGF) for the Treatment of Macular Edema of Various
Etiologies: A Short-term Pilot Study. Martin A. Serrano. May 6, 11:15am.
#1696. Endophthalmitis After Intravitreal Injections: In-office Setting Vs Operating Room Setting. Alessandra Sborgia. May 7, 8:30am.
#1880. Superselective Intra-arterial Chemotherapy For Retinoblastoma Treatment: Comparative Pharmacokinetics Of Topotecan And Melphalan In The
Swine Model. Emiliano F. Buitrago. May 7, 1:45pm.
#4179. Real-world Utilization of Intravitreal Anti-Vascular Endothelial Growth
Factor Agents in Common Retinal Diseases. Nancy M. Holekamp. May 9,
8:30am.
#6927. Bevacizumab for Macular Edema in Central Retinal Vein Occlusion: A
prospective, randomized, double-blind clinical study. David L. Epstein. May 10,
1:15pm.
236 laser - RE
#417. Sub-threshold Laser Treatment of Macular Edema in Patients with
Diabetes. Anat Loewenstein. May 6, 8:30am.
237 lens - LE
#1052. Evaluation of the Biocompatibility of a New Cyanine Dye for Lens
Capsule Staining. Peter Laubichler. May 6, 11:15am.
#1066. Sulforaphane Can Protect Human Lens Cells Against Oxidative Stress.
Hanruo Liu. May 6, 11:15am.
#1726. iSyTE: integrated Systems Tool for Eye Gene Discovery. Salil A.
Lachke. May 7, 1:45pm.
#3048. Efficient Generation of Lens Progenitor Cells from Cataract Patientspecific Induced Pluripotent Stem Cells. Xiaodi Qiu. May 8, 8:30am.
#3059. Clinical Study of alpha crystallin, the lens molecular chaperone, in the
various lens compartments in normal subjects and cataract patients using
Dynamic Light Scattering. Qing Pan. May 8, 8:30am.
Complete meeting information is available at www.arvo.org/am
117
Emerging Trends and Hot Topics
#3664. Evaluation of Supranuclear Lens Changes in Alzheimer’s Disease
Patients using Scheimpflug Imaging 3-Dimensional Densitometry. Margaret P.
Liu. May 8, 3:45pm.
#4145. Mesenchymal and Neural Crest Markers in the Embryonic Lens. A S.
Menko. May 9, 8:30am.
#4147. Expression of the Small Heat Shock Protein αΒ- crystallin is Controlled
by a Gene-specific Sequence in its Promoter. Suraj P. Bhat. May 9, 8:30am.
#6912. Evaluation Of Doxorubicin Loaded Mepeg-pcl Nanoparticle For Prevention Of Posterior Capsular Opacification. Aditya Konar. May 10, 1:15pm.
238 lens development and differentiation - LE
#5591. Inactivation of JNK Signals Formation Of The Organelle Free Zone
(OFZ), A Process That Involves Classical Autophagic Molecules. Subhasree
Basu. May 10, 8:30am.
240 low vision - VI
#3151. Characteristics of the On-road Driving performance of Persons with
Central Vision Loss using Bioptic Telescopes. Joanne M. Wood. May 8, 1:45pm.
241 macular degeneration: inherited - RC
#6888. Canine Bestrophinopathies: Lesion Morphology and Molecular Pathology. Karina E. Guziewicz. May 10, 1:15pm.
242 macular diseases except AMD - RE
#1752. Staging of Progression of Macular Telangiectasia Type 2 Using PowerDoppler Optical Coherence Tomography and Macular Pigment Optical Density.
Eric K. Chin. May 7, 1:45pm.
#1753. Adaptive Optics Scanning Laser Ophthalmoscopy Demonstrates
Reduced Foveal Cone Density in Early Idiopathic Macular Telangiectasia. Mina
M. Chung. May 7, 1:45pm.
#5201. Histopathology of Optic Nerve Pit associated Maculopathy. William D.
Terrell. May 9, 1:45pm.
#5207. Modelling Best Vitelliform Macular Dystrophy with human embryonic
stem cells. Michael D. O’Connor. May 9, 1:45pm.
#5208. Distinct Patterns of Foveal Degeneration in Occult Macular Dystrophy.
Sarwar Zahid. May 9, 1:45pm.
#5209. Photoreceptor Structure in the Spectrum of Best Vitelliform Macular
Dystrophy. Megan E. Land. May 9, 1:45pm.
#5212. Clinical and SD-OCT Findings in Focal Choroidal Excavation. Stefano
Erba. May 9, 1:45pm.
#5224. Metamorphopsia in Eyes with Chronic Central Serous Chorioretinopathy; One year after Half-dose Verteporfin Photodynamic Therapy. Yoshihiro
Mizutani. May 9, 1:45pm.
118
Complete meeting information is available at www.arvo.org/am
Emerging Trends and Hot Topics
243 macular edema - RE
#415. The Effect of Hemoglobin A1c on Bevacizumab Response in Patients
with Diabetic Macular Edema. Irene Rusu. May 6, 8:30am.
#923. The Efficacy Of Intravitreal Bevacizumab For Macula Edema Of Retinal
Vein Occlusion. Shigehiro Iwabuchi. May 6, 11:15am.
#6928. Long Term Evaluation of the Visual Prognosis in Patients Treated With
Dexamethasone Intravitreal Implant (Ozurdex) for Macular Edema Due to
Retinal Vein Occlusion. Elad Moisseiev. May 10, 1:15pm.
#6929. Intravitrial Aflibercept Injection for Macular Edema in Central Retinal
Vein Occlusion: 1-year Results of the Phase 3 GALILEO Study. Frank G. Holz.
May 10, 1:15pm.
#6930. Macular Edema After Uneventful Phacoemulsification Detected By
Ocular Coherence Tomography (OCT). Luiz Felipe Q. Silveira. May 10, 1:15pm.
#6931. Clinical Classification of Autosomal Dominant Cystoid Macular Edema
and Genetic Fine Mapping of the Underlying Defect. Nicole T. Saksens. May
10, 1:15pm.
#6933. C-REALITY (Canadian Burden of Diabetic Macular Edema Observational Study). John R. Gonder. May 10, 1:15pm.
244 macular pigment and carotenoids - BI
#3362. Innovative Troxler-free Measurement of Macular Pigment and Lens
Density with Correction of the Former for the Aging Lens. Richard A. Bone.
May 8, 1:45pm.
#3380. The Ring Like Distribution Profile Of Macular Pigment Appears Highly
Heritable: A Twin Study. Erik F. van Kuijk. May 8, 1:45pm.
251 molecular pharmacology - PH
#5321. Effect of Fenugreek on Severe Evaporative Dysfunctional Tear Syndrome. Caterina Gagliano. May 9, 3:45pm.
252 myopia - AP
#4444. Genetic Factors For Choroidal Neovascularization Associated With
High Myopia. Nicolas Leveziel. May 9, 8:30am.
255 nanomedicine, nanopharmaceuticals,
nanotherapy - NT
#3638. Sustained Therapeutic Effects of Nanoceria In A Mouse Model For
AMD. Xue Cai. May 8, 3:45pm.
256 nanoparticles, nanobiosensors, nanobiomarker,
nanophotonics, nanobioelectronics, nanofluids - NT
#294. Polyethyleneimine (PEI) Nanoparticle-mediated Soluble TGFβRII Gene
Transfer Prevents Corneal Fibrosis. Jason T. Rodier. May 6, 8:30am.
258 neural retina: dysfunction in disease - VN
#4650. Retinal Ganglion Cell Dendritic Degeneration in a Mouse Model Of
Alzheimer’s Disease. Marcela Votruba. May 9, 1:45pm.
Complete meeting information is available at www.arvo.org/am
119
Emerging Trends and Hot Topics
260 neuro-ophthalmology - EY
#1312. Non-mydriatic Ocular Fundus Photography Read by Emergency
Department (ED) Physicians: FOTO-ED Study. Beau B. Bruce. May 7, 8:30am.
#1313. Overview of Progress on the 256+ Channel Boston Retinal Prosthesis.
Joseph F. Rizzo, III. May 7, 8:30am.
#4896. Ethnic Differences In The Presentation And Characteristics Of Oculomotor Nerve Palsy. Matthew M. Kruger. May 9, 1:45pm.
#4898. Non-Mydriatic Fundus Photography of the Ocular Fundus in Headache
Patients Presenting to an Emergency Department. Praneetha Thulasi. May 9,
1:45pm.
261 neuro-ophthalmology: visual fields and psychophysics - EY
#4838. Web-accessible Visual Field Test and Analysis System for Multi-Center
Studies and Touchpad Device Access. Wolfgang Fink. May 9, 1:45pm.
#4845. Alzheimer’s Disease: Frequency Doubling Technology Biomarkers in
the Visual System. Denise A. Valenti. May 9, 1:45pm.
264 non-infectious uveitis - IM
#4163. CFH and HTRA1 risk alleles in Caucasian and African American ocular
sarcoidosis patients. Ian A. Thompson. May 9, 8:30am.
#4169. Methotrexate vs. Mycophenolate Mofetil for Ocular Inflammatory
Diseases. John H. Kempen. May 9, 8:30am.
#5273. Canonical Wnt Signalling Is Active During The Peak Of Uveitis And
Can Regulate Macrophage Activation. Tarnjit K. Khera. May 9, 3:45pm.
#5481. Soluble Interleukin 2 Receptor, Angiotensin Converting Enzyme, And
Neopterin in Screening Ocular Sarcoidosis And Monitoring Disease Activity.
Thomas Ness. May 9, 3:45pm.
#5497. Glucocorticoid Increases Cd14HighCd16+ Monocyte Population And
Contributes To Uveitis Therapy. Baoying Liu. May 9, 3:45pm.
#5498. Idiopathic Panuveitis Associated With Retinitis Pigmentosa. Diana
Pachon. May 9, 3:45pm.
272 optic nerve - EY
#2986. Adenosine Agonist Combating Inflammation In Traumatic Optic Neuropathy. Nadeem H. Fatteh. May 8, 8:30am.
#3163. Post-NAION Demyelination: Treatment Targeting. Steven L. Bernstein.
May 8, 1:45pm.
275 optical coherence tomography - MOI
#2106. Prevalence of Macular Anatomic Abnormalities in Eyes with High
Myopia. Andree Henaine-Berra. May 7, 1:45pm.
#2108. An SD-OCT Assessment of Retinal Pigment Epithelium Tears Risk in
Pigment Epithelium Detachment. Francesco Pichi. May 7, 1:45pm.
120
Complete meeting information is available at www.arvo.org/am
Emerging Trends and Hot Topics
#2118. Change in Choroidal Thickness Measurements in Diabetic Patients
using Spectral Domain OCT. Steven L. Williams. May 7, 1:45pm.
281 photoreceptors: development - RC
#3940. Partial Reprogramming of Adult Mouse Rods Into Cones Rescues
Retinal Degeneration. Cynthia L. Montana. May 8, 3:45pm.
290 regenerative medicine - NT
#268. Induction Of Corneal Epithelial Cells From Human-induced Pluripotent
Stem Cells On The Amniotic Membrane Matrix. Morio Ueno. May 6, 8:30am.
292 retina/RPE: biochemistry and molecular biology - BI
#1592. Interphotoreceptor Retinoid Binding Protein (IRBP) - a Thiol Based
Antioxidant in the Subretinal Space. Dongjin Sung. May 7, 8:30am.
#1630. Zebrafish snow white as a model for Hermansky-Pudlak Syndrome.
Christina M. Daly. May 7, 8:30am.
#2216. Spatial Distribution Of Lipid Molecular Species In Photoreceptors And
Other Cells By Maldi Imaging Mass Spectrometry Of The Human Retina.
Nicolas G. Bazan. May 7, 3:45pm.
#2218. Identification of the Vitamin A Isomerase in Retinal Müller Cells. Joanna J. Kaylor. May 7, 3:45pm.
293 retina/RPE: cell biology - RC
#6549. Therapeutic Inhibition Of Retinoblastoma By Nanoceria. Kathryn E.
Klump. May 10, 11:15am.
294 retina/RPE: cell death, autophagy, oxidation,
ER stress - RC
#4284. Effects of Bevacizumab on Bcl-2 Expression and Apoptosis in Retinal
Pigment Epithelial Cells under Oxidative Stress. Suk Jin Kim. May 9, 8:30am.
#4299. The Further Opening Of The DHA Metabolome In Retinal Pigment
Epithelial (RPE) Cells: Maresin Synthesis Diverges From NPD1 Synthesis By
Enhanced Oxidative Stress. Bokkyoo Jun. May 9, 8:30am.
295 retina/RPE: development - RC
#1315. Olig2 Defines Subpopulations Of Retinal Progenitor Cells Biased
Towards Specific Cell Fates. Brian P. Hafler. May 7, 8:30am.
297 retina/RPE: immunobiology and infection - IM
#1227. Treatment With Recombinant Interleukin-17A Reduces ARPE-19 Cell
Viability. Daniel Ardeljan. May 6, 3:15pm.
#2782. Phagocytosis and Replication of Mycobacterium Tuberculosis in Retinal
Pigment Epithelium. Hossein Nazari Khanamiri. May 8, 8:30am.
#2783. Syphilis On The Rise: Ocular Presentations Seen At Moorfields Eye
Hospital. Zaman K. Durani. May 8, 8:30am.
#5275. Neuronal Inflammasome Facilitates Il-1β Release And Ganglion Cell
Loss In Retinal Ischemia-reperfusion. Valery I. Shestopalov. May 9, 3:45pm.
Complete meeting information is available at www.arvo.org/am
121
Emerging Trends and Hot Topics
299 retina/RPE: transpantation, clinical - RE
#5843. Adipose derived Mesenchymal stem cells partially rescue the Mitomycin C treated ARPE19 from cell death in co-culture. Jose-Carlos Pastor. May
10, 8:30am.
301 retina: physiology/pharmacology - PH
#4157. Complement Factor H Gene Polymorphism Plays A Role In The Regulation Of Vascular Tone In The Choroid. Reinhard Told. May 9, 8:30am.
302 retinal detachment - RE
#4602. A Novel Surgical Technique For Encircling Scleral Buckle Surgery For
Primary Retinal Detachment. Dimitra Skondra. May 9, 8:30am.
#5791. Triamcinolone-Assisted Internal Limiting Membrane Peeling During
Primary Rhegmatogenous Retinal Detachment Repair Reduces Postoperative
Macular Pucker Formation. Rajesh C. Rao. May 10, 8:30am.
#6356. Outcomes of Scleral Buckle Removal Combined with Prophylactic
Laser Retinopexy. Mohammed Khuthaila. May 10, 11:15am.
#6357. Evolution Of Partial-thickness Macular Folds Occurring After Vitrectomy
For Retinal Detachment Repair. Roberto dell’Omo. May 10, 11:15am.
303 retinal development: cell biology and morphology - RC
#3951. Linc Complexes Mediate The Apical Positioning Of Mouse Cone Photoreceptor Nuclei. Didier M. Hodzic. May 8, 3:45pm.
#3967. SOX2 Maintains the Quiescence of Müller Glial Cells. Tessa Crowl. May
8, 3:45pm.
309 retinal inflammation and infection - IM
#2756. Efficacy And Safety Of Posterior Sub-tenon Triamcinolone Injection
Using A Cannula For The Treatment Of Uveitic Cystoid Macular Oedema.
Stephen J. Turner. May 8, 8:30am.
#2779. CD40 Expressed on Endothelial Cells Enhances Resistance to Ocular
Toxoplasmosis. Carlos Subauste. May 8, 8:30am.
311 retinal prostheses - RE
#5507. Subjects Blinded By Outer Retinal Dystrophies Are Able To Recognize
Outlined Shapes Using The Argus® Ii Retinal Prosthesis System: A Comparison With The Full Shapes Recognition Task. Lyndon daCruz. May 9, 3:45pm.
#5508. Visual Performance Measures Correlate According to Two Independent
Task-Solving Abilities in Argus® II Subjects. Thomas Z. Lauritzen. May 9,
3:45pm.
#5509. Successful Target Identification with the Argus® II Retinal Prosthesis.
Michael P. Barry. May 9, 3:45pm.
#5511. Functional vision and quality of life of Argus® II Retinal Prosthesis
System users as measured by the Functional Low-vision Observer Rated
Assessment (FLORA). Jessy D. Dorn. May 9, 3:45pm.
122
Complete meeting information is available at www.arvo.org/am
Emerging Trends and Hot Topics
#5512. A Safe CMOS Stimulation and Communications Chip for Retinal
Implants. John L. Wyatt, Jr. May 9, 3:45pm.
#5526. Holographic Acoustic Retinal Stimulation. Omer Naor. May 9, 3:45pm.
#5527. Selectivity of Epiretinal Stimulation Depends on Waveform and Pulse
Width. Susanne Pangratz-Fuehrer. May 9, 3:45pm.
#5533. Pulse Duration Optimization with Retinal Prosthetics. Shelley I. Fried.
May 9, 3:45pm.
#5535. Evaluation of inner-retina using OCT and Transcorneal Electrical Stimulation (TES) in Candidates of Retinal Prosthesis by Suprachoroidal-transretinal
Stimulation (STS). Takashi Fujikado. May 9, 3:45pm.
#5537. Mouse Retinal Ganglion Cell Responses to Sub-Retinal Electrical
Excitation by High-Density Retinal Prosthesis Chips. Long-Sheng Fan. May 9,
3:45pm.
#5539. Mobility Experiments Using Simulated Prosthetic Vision With 98 Phosphenes Of Limited Dynamic Range. Paulette Lieby. May 9, 3:45pm.
#5547. Retinal Prostheses: Monocular Depth Perception In the Low Resolution
Limit. Noelle R. Stiles. May 9, 3:45pm.
#5548. How Blind Is A Flat ERG? - An Improved Method Of Assessing Retinal
Function In Patients With Extremely Poor Vision. Lauren N. Ayton. May 9,
3:45pm.
#6948. Seeing With Subretinal Electronic Implants: Study in Ten Patients With
Wireless Implant Alpha-IMS. Eberhart Zrenner. May 10, 1:15pm.
#6952. Patients blinded by outer retinal dystrophies are able to perceive
simultaneous colors using the Argus® II Retinal Prosthesis System. Paulo E.
Stanga. May 10, 1:15pm.
#6953. Results Update from Second Sight’s Argus® II Retinal Prosthesis
Study. Mark S. Humayun. May 10, 1:15pm.
313 retinal (neural and RPE) degeneration - RC
#5506. Extinguished ERGs And Retinal Function In Usher Syndrome. Anne
Kurtenbach. May 9, 3:45pm.
314 retinitis pigmentosa - RE
#4567. The Clinical Effect of Homozygous ABCA4 Alleles in 14 Patients. Kaoru
Fujinami. May 9, 8:30am.
#4571. Neuroprotective Efficacy Of Topical Unoprostone Isopropyl In Patients
With Retinitis Pigmentosa. Masato Akiyama. May 9, 8:30am.
#4581. Change in Visual Function after UF-021 Therapy for Retinitis Pigmentosa. Akira Hagiwara. May 9, 8:30am.
Complete meeting information is available at www.arvo.org/am
123
Emerging Trends and Hot Topics
#4590. Para-arterial Sparing Phenotype In Leber Congenital Amaurosis Associated
With Homozygous p.R108X SPATA-7 Mutation. Anne Kuonen. May 9, 8:30am.
#4591. Retinal Structure and Function in a Pedigree Cosegregating Achromatopsia and a Rhodopsin Mutation. Andrea L. Vincent. May 9, 8:30am.
#4594. Alternative Splicing of Exon 12 of the Male Germ Cell Associated Kinase
Gene (MAK) Results in a Cone-specific Isoform. Edwin M. Stone. May 9, 8:30am.
#4595. Clinical Features In Patients With Cone-Rod Dystrophy Or Retinitis
Pigmentosa Due To Mutations In C8orf37. Ramon A. van Huet. May 9, 8:30am.
#4597. Structural and Functional Correlations of Hyperautofluorescent Foveal
Patch in Usher Syndrome Patients. Ana Fakin. May 9, 8:30am.
#4598. An Adenine Insertion between Nucleotide Positions 4957 and 4958 in
the EYS Gene Is a Possible Major Cause of arRP in the Japanese Population.
Katsuhiro Hosono. May 9, 8:30am.
315 retinopathy of prematurity - RE
#4684. Systemic And Ocular Adverse Events After 334 Injections Of Intravitreal Bevacizumab In The Treatment Of ROP: Five-Year Follow-Up In 3 Centers.
Maria A. Martinez-Castellanos. May 9, 1:45pm.
#4686. Plus Disease In Retinopathy Of Prematurity: Qualitative Analysis Of
Diagnostic Process By Experts. Michael F. Chiang. May 9, 1:45pm.
#5853. Long-term Follow-up Of The Adults With Retinopathy Of Prematurity
Who Received Photocoagulation And Cryopexy Treatments. Hiroki Kaneko.
May 10, 8:30am.
#5865. Plus Disease Diagnosis In Retinopathy Of Prematurity: Vascular
Tortuosity As A Function Of Distance From Optic Disc Center. Katie M. Keck.
May 10, 8:30am.
#5866. Aggressive posterior retinopathy of prematurity: Quantitative analysis of
vascular features. Rany Woo. May 10, 8:30am.
#5873. Macular Pigment Imaging in Infants and Children Using the RetCam.
Paul S. Bernstein. May 10, 8:30am.
#5875. Influence of Foveal Photoreceptor Sub-Elements On Visual Acuity
In Premature Infants With And Without Retinopathy Of Prematurity. Anand
Vinekar. May 10, 8:30am.
#5884. Systemic Safety After Intravitreal Bevacizumab Injection In Newborn
Rabbit Eyes. Wei-Chi Wu. May 10, 8:30am.
316 ROP-basic mechanisms - RC
#2528. Mixed Arterial-Venous PO2 Levels Critical to Ocular Markers of Angiogenesis and Oxidative Stress in Neonatal Rats. William J. Brunken. May 7, 3:45pm.
#2532. A Descriptive Analysis of Surfactant Proteins in the Mouse Retina.
Faizah N. Bhatti. May 7, 3:45pm.
124
Complete meeting information is available at www.arvo.org/am
Emerging Trends and Hot Topics
#2534. Prolyl Hydroxylase Inhibition during Hyperoxia Prevents Oxygen-induced Retinopathy in the Rat 50/10 Model. George Trichonas. May 7, 3:45pm.
#6296. Activation of the Endothelin System in Models of Ischemic Retinopathy.
Chintan Patel. May 10, 11:15am.
319 stem cells - RC
#342. Adult Dental Pulp Stem Cells Present Similarities Between Dental Pulp
From Deciduous Teeth and Human Limbal. Priscila C. Cristovam. May 6, 8:30am.
#2692. Retinal Laminae Formation and Synapse Development in Optic
Vesicle-like Structures Isolated from Human Blood-derived iPS Cells. Joe
Phillips. May 8, 8:30am.
#2693. Targeting Human Mak Mutant iPSCs For In Vitro Gene Replacement.
Budd A. Tucker. May 8, 8:30am.
#5900. Transfer of mRNA and Micro-RNA by Embryonic Stem Cell-Derived
Microvesicles Induces Gene Expression Changes in Retinal Progenitor Müller
Cells. Diana Katsman. May 10, 8:30am.
327 tumors - AP
#1288. Ocular Histopathology of a Non-Human Primate Model of Super-Selective
Intra-Ophthalmic Artery Chemotherapy. Matthew W. Wilson. May 7, 8:30am.
#1291. Nodal Signaling Pathway: A Novel Developmental Pathway Possibly
Driving Retinoblastoma Tumorigenesis. Geeta K. Vemuganti. May 7, 8:30am.
#1293. Epigenetic therapy targeting SYK in Preclinical Models of Retinoblastoma. Rachel Brennan. May 7, 8:30am.
#1877. Melphalan-Induced Injury in Human Primary Retinal Endothelial Cells:
A Novel Flow-Based Investigation. Jordan J. Toutounchian. May 7, 1:45pm.
#1878. Effects of Supra-Selective Intra-Ophthalmic Artery Chemotherapy (SSIOAC)
on Orbital Arteries in a Non-Human Primate Model. Brian C. Tse. May 7, 1:45pm.
#3395. Tris (dibenzyldineacetone) Dipalladium Suppresses Primary Ocular
Melanoma And Its Hepatic Metastases In A Murine Ocular Melanoma Model.
Hans E. Grossniklaus. May 8, 1:45pm.
#3419. Estimation Of Cancer Risk Associated With Metastatic Surveillance
Imaging For Choroidal Melanoma. Joanne C. Wen. May 8, 1:45pm.
#5251. BAP1 Protein Expression In UM; High Throughput Analysis Using
Tissue Microarrays Of Primary Uveal Melanoma And Liver Metastases. Helen
Kalirai. May 9, 3:45pm.
#5254. A Web-based Tool For Prognosis Of Patients With Choroidal Melanoma
Using Accelerated Failure Time Model. Azzam F. Taktak. May 9, 3:45pm.
330 tumors: new drugs, delivery systems, and mechanisms of action - PH
#6867. Intra-arterial Chemotherapy for the Management of Retinoblastoma in Eyes
with Extensive (>50%) Retinal Detachment. Sotiria Palioura. May 11:15am.
Complete meeting information is available at www.arvo.org/am
125
Emerging Trends and Hot Topics
331 tumors: posterior segment, clinical - RE
#3388. Diffuse versus Non-diffuse Choroidal Melanoma: Comparative study.
Swathi Kaliki. May 8, 1:45pm.
#3405. Brachytherapy of large uveal melanomas. Michael Freistuehler. May 8,
1:45pm.
#3412. Stereotactic Radiosurgery Of Uveal Melanoma With And Without
Tumor Resection With Respect To Local Tumor Control And Eye Retention.
Daniela Suesskind. May 8, 1:45pm.
#3423. Hepatic Arterial Chemoembolization (HACE) For Uveal Melanoma
Metastatic To The Liver. Tahira Mathen. May 8, 1:45pm.
332 uveitis: posterior - RE
#1186. The Effect Of Pars Plana Vitrectomy On Macular Edema Sustained By
Macular Pucker In Uveitis Patients: Long Term Results. Matteo G. Cereda. May
6, 3:15pm.
#1189. Ultra-wide-field Angiography Improves Detection Of Uveitic Retinal
Vascular Retinopathy. Darby D. Miller. May 6, 3:15pm.
#1193. Indirect Supportive Evidence for Tuberculosis-Related Uveitis. From the
Ancient TST to the New IGRAs. Victor Llorens. May 6, 3:15pm.
#1202. Distinctive Clinical Features of Idiopathic vs Infectious Serpiginous
Choroidopathy. Ester Carreno. May 6, 3:15pm.
#2247. Flucinolone Acetonide Implant (RETISERT) in the Management of
Vogt-Koyanagi-Harada Disease. Jang won Heo. May 7, 3:45pm.
#2248. Voclosporin for Noninfectious Uveitis Involving the Posterior Segment: New
Analyses of the LUMINATE Phase 2/3 Trials. Pravin U. Dugel. May7, 3:45pm.
#2251. Primary Endpoint Results Of The SAVE Study - Sirolimus As
Therapeutic Approach To UveItis: A Randomized Study To Assess The Safety
And Bioactivity Of Intravitreal And Subconjunctival Injections Of Sirolimus In
Patients With Non-infectious Uveitis. Quan Dong Nguyen. May 7, 3:45pm.
#3200. Use Of Immunosuppressive Therapy In Patients With APMPPE,
Ampiginous Choroiditis And Serpiginous Choroiditis. Mirjam E. Van Velthoven.
May 8, 1:45pm.
#3204. EDI-OCT in Punctate Inner Choroidopathy: Correlation of Choroidal
Thickness and Choroidal Volume with Duration of the Disease. Javier ZarranzVentura. May 8, 1:45pm.
#3220. Modulating The Severity Of Uveitis By Altering RPE Barrier Function:
Implication In Therapeutics. Yun-Zheng Le. May 8, 1:45pm.
#3221. LPS-Activated Tolerogenic Dendritic Cells which Suppress Experimental Autoimmune Uveoretinitis fail to signal via TBK1/IRF3. Izabela P. Klaska.
May 8, 1:45pm.
126
Complete meeting information is available at www.arvo.org/am
Emerging Trends and Hot Topics
337 visual cycle and retinoids - BI
#2213. Primary Amines Protect The Retina From Degeneration In Mouse Models: Implications For Stargardt’s Disease And Age-related Macular Degeneration. Akiko Maeda. May 7, 3:45pm.
340 visual function and quality of life - CL
#4627. What is the value of a mm Hg reduction in intraocular pressure? Results
from the Glaucoma Health Policy Model. Andreas M. Pleil. May 9, 1:45pm.
341 visual impairment: prevalence, incidence and
risk factors - CL
#3175. The Global Burden of Disease Study: the Impact of Vision Loss: prevalence and trends of blindness and visual impairment over the past 28 years.
Rupert R. Bourne. May 8, 1:45pm.
345 vitreoretinal surgery - RE
#2599. Eliminating Infusion Bubbles And Uncontrolled Reflux By The Constellation Vitrectomy System. Stephen R. Russell. May 7, 3:45pm.
#2600. Vitreoretinal Traction of the new generation pneumatic cutters - up than
5000 CPM. Anderson Teixeira. May 7, 3:45pm.
#2627. The Effect of Diabetes on Cataract Progression in Patients who had
done Pars plana vitrectomy. Jin Cheol Lee. May 7, 3:45pm.
#2632. Retinal Toxicity of Lutein and Zeaxanthin associated to Brilliant Blue in
Rabbit Model. Diogo Sousa-Martins. May 7, 3:45pm.
#2750. An Overview On Transchoroidal Surgery For Subretinal Visual Prosthetic
Devices On The First 20 Blind Rp-patients. Helmut G. Sachs. May 8, 8:30am.
#2751. Sutureless Small Gauge Vitrectomy for Relief of Symptomatic Vitreous
Floaters. John O. Mason, III. May 8, 8:30am.
#2752. Immunohistochemistry Detects Inner Retina in Excised Membranes
from Vitreo-Maculopathies with Poor Post-Operative Vision. Kenneth M. Yee.
May 8, 8:30am.
#2754. The Phase III MIVI-TRUST Clinical Trial Data: Subgroup Responder
Analysis of a Single Intravitreal Injection of Ocriplasmin in patients with Vitreomacular Traction. Baruch D. Kuppermann. May 8, 8:30am.
#3767. Long-Term In Vivo Biocompatibility of UV-Cross-Linked Hyaluronic Acid as
Vitreous Replacement - 12 Months Results. Martin S. Spitzer. May 8, 3:45pm.
#3790. Use of Lutein and Zeaxanthin Alone or Combined with Brilliant or Trypan Blue to Identify Intraocular Structures Intraoperatively in Cadaveric Eyes.
Mauricio Maia. May 8, 3:45pm.
#3797. A Novel Surgical Method and Support Device for Translocating Autologous Tissue Grafts to the Sub-Area Centralis: In vivo Porcine Model. Timothy
W. Olsen. May 8, 3:45pm.
Complete meeting information is available at www.arvo.org/am
127